Not bad for nine months' work. Mylan CEO and Vice Chairman Robert Coury (photo [1]) brought down $10.3 million during fiscal 2007, which ran only nine months because the drugmaker changed its fiscal year.
Coury earned salary of about $1.12 million, stock awards of $1.15 million, and about $2.1 million in incentive compensation, the Pittsburgh Business Times reports. During the previous fiscal year, Coury was paid about $8.6 million. How does this compare to other drugmakers' executive pay? Well, it beats Pfizer's Jeff Kindler ($9.5 million [2]) but doesn't outstrip Bristol-Myers Squibb's Jim Cornelius ($11.3 million [3]) or even Cephalon's Frank Baldino ($13.5 million [4]).
- read the Business Times story [5]
ALSO: A federal appeals court affirmed a ruling that prevents Mylan from selling a copycat form of Johnson & Johnson's Topamax before the epilepsy med's patent expires later this year. Report [6]
Related Articles:
Mylan CEO intent on new global biz. Report [7]
Glaxo to let Mylan make generic Paxil. Report [8]
Links:
[1] http://www.fiercebiotech.com/pages/mylan-ceo-robert-coury
[2] http://www.fiercepharma.com/story/wyeth-pfizer-chiefs-see-pay-decline/2008-03-17
[3] http://www.fiercepharma.com/story/bms-chief-nabs-10-million-raise/2008-03-25
[4] http://www.fiercepharma.com/story/cephalon-pays-ceo-more-than-hefty-rivals/2008-03-26
[5] http://www.bizjournals.com/pittsburgh/stories/2008/03/31/daily7.html
[6] http://online.wsj.com/article/SB120698009540277349.html?mod=googlenews_wsj
[7] http://www.fiercepharma.com/story/mylan-ceo-intent-new-global-biz/2007-12-10
[8] http://www.fiercepharma.com/story/glaxo-let-mylan-make-generic-paxil/2007-10-23